Oncolix, Inc., Announces Submission of Application for Listing on OTC-QB

OTC-QB listing anticipated to be finalized before the end of the year


HOUSTON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Oncolix, Inc., (OTC PINK:ONCX) announced today that following the appointment of the second independent member of the Board of Directors the Company has fulfilled the requirements and has submitted an application to be listed on the OTC-QB. The review is anticipated to take approximately two to four weeks after which Oncolix would be listed on the OTC-QB.

“We continue to make progress building out our public biopharmaceutical company infrastructure and today, we are finally able to realize an important step by submitting the application for listing on the OTC-QB,” said Michael T. Redman, chief executive officer of Oncolix. “We continue to meet our announced milestones, most recently changing the company name and stock ticker, appointing two independent members to our board of directors, and finishing an extensive review process by the Financial Industry Regulatory Authority (FINRA). All of these actions are directed toward our ultimate objective of a NASDAQ listing.”

About Oncolix

Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in its first indication, the treatment of ovarian cancer.  This Phase 1 clinical trial is currently in progress. Prolanta™ is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently $2 million), federal tax credits and marketing exclusivity.

Forward-Looking Statements

This press release above may contain forward‐looking statements about the business, financial condition and prospects of the Company. Forward looking statements can be identified by the use of forward-looking terminology such as “believes,” “projects,” “expects,” “may,” “goal,” “estimates,” “should,” “plans,” “targets,” “intends,” “could,” or “anticipates,” or the negative thereof, or other variations thereon, or comparable terminology, by discussions of strategy or objectives.  Forward-looking statements relate to anticipated or expected events, activities, trends or results.  Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties.

Although the Company believes that the expectations reflected in forward-looking statements are reasonable, there can be no assurances that such expectations will prove to be accurate.  Security holders are cautioned that such forward-looking statements involve risks and uncertainties. The forward-looking statements contained in the press release speak only as of the date of the press release, and the Company expressly disclaims any obligation or undertaking to report any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based. Certain factors may cause results to differ materially from those anticipated by some of the statements made in the press release. Investors are urged to consider closely the disclosures in our Forms 10-K, 10-Q, 8-K and other filings with the SEC, which can be electronically accessed from the SEC's website at http://www.sec.gov/.

Corporate contact:

Michael Redman
P: 281-402-3167
E: mredman@oncolixbio.com

Investor contact:
The Ruth Group
Robert Flamm, Ph.D.
P: 646-536-7017
E: rflamm@theruthgroup.com